

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: IFT1/19 - Immunophenotypisation

Dead line: 15.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(253) CD 3+ T lymphocytes</b>					100							100	91	91%
Samples and groups	[%]													
<b>Sample A</b>		58,0	1,5	2,5	100	CVP	58	0,36	7%	53,9	62,1	100	95	95%
(12) Beckman Coulter		58,2	1,4	2,5	50	0						50		
(88) Becton Dickinson		57,8	1,4	2,5	27	0						27		
(177) MINDRAY		57,5	2,2	3,9	8	0						8		
(190) Exbio Praha		57,7	0,68	1,2	9	0						9		
Other					6	0						6		
							1x 28, 4x 36, 1x 999							
<b>Sample B</b>		77,7	2,2	2,8	100	CVP	77,7	0,54	7%	72,2	83,2	100	96	96%
(12) Beckman Coulter		77,9	2,1	2,6	50	0						50		
(88) Becton Dickinson		77,3	2,0	2,5	27	0						27		
(177) MINDRAY		77,1	3,0	3,9	8	0						8		
(190) Exbio Praha		78,4	1,9	2,4	9	0						9		
Other					6	0						6		
							1x 28, 4x 36, 1x 999							
<b>(254) CD 4+ T lymphocytes</b>					100							100	91	91%
Samples and groups	[%]													
<b>Sample A</b>		49,8	1,5	3,1	100	CVP	49,8	0,38	10%	44,8	54,8	100	93	93%
(12) Beckman Coulter		50,2	1,5	3,0	51	0						51		
(88) Becton Dickinson		49,6	1,2	2,5	27	0						27		
(177) MINDRAY		48,9	2,7	5,6	8	0						8		
(190) Exbio Praha		50,1	0,74	1,5	7	0						7		
Other					7	0						7		
							4x 36, 3x 999							
<b>Sample B</b>		44,2	1,7	3,9	100	CVP	44,2	0,42	10%	39,7	48,7	100	96	96%
(12) Beckman Coulter		44,3	1,7	3,7	51	0						51		
(88) Becton Dickinson		44,3	1,5	3,3	27	0						27		
(177) MINDRAY		43,5	1,0	2,4	8	0						8		
(190) Exbio Praha		45,5	2,4	5,3	7	0						7		
Other					7	0						7		
							4x 36, 3x 999							
<b>(255) CD 8+ T lymphocytes</b>					100							100	92	92%
Samples and groups	[%]													
<b>Sample A</b>		7,30	0,54	7,5	100	CVP	7,3	0,13	17%	6,05	8,55	100	92	92%
(12) Beckman Coulter		7,23	0,52	7,2	52	0						52		
(88) Becton Dickinson		7,37	0,43	5,8	25	0						25		
(177) MINDRAY		7,20	1,2	16	8	0						8		
(190) Exbio Praha		7,00	0,73	10	7	0						7		
Other					8	0						8		
							1x 28, 4x 36, 3x 999							
<b>Sample B</b>		29,4	1,7	5,7	100	CVP	29,4	0,41	17%	24,4	34,4	100	99	99%
(12) Beckman Coulter		29,1	1,7	6,0	52	0						52		
(88) Becton Dickinson		29,7	1,7	5,6	25	0						25		
(177) MINDRAY		31,0	1,9	6,0	8	0						8		
(190) Exbio Praha		28,2	1,5	5,3	7	0						7		
Other					8	0						8		
							1x 28, 4x 36, 3x 999							
<b>(256) B lymphocytes</b>					100							100	97	97%
Samples and groups	[%]													
<b>Sample A</b>		19,4	1,1	5,4	100	CVP	19,4	0,26	30%	13,5	25,3	100	99	99%
(12) Beckman Coulter		19,2	1,1	5,8	54	0						54		
(36) Immunotech		19,6	1,8	9,1	6	0						6		
(88) Becton Dickinson		19,5	0,91	4,7	22	0						22		
(177) MINDRAY		19,7	1,3	6,7	8	0						8		
(190) Exbio Praha		19,4	0,57	2,9	9	0						9		
Other					1	0						1		
							1x 999							
<b>Sample B</b>		11,3	0,85	7,5	100	CVP	11,3	0,21	30%	7,91	14,7	100	97	97%
(12) Beckman Coulter		11,2	0,86	7,6	54	0						54		
(36) Immunotech		10,7	2,0	19	6	0						6		
(88) Becton Dickinson		11,4	0,76	6,7	22	0						22		
(177) MINDRAY		12,0	1,5	12	8	0						8		
(190) Exbio Praha		11,0	0,52	4,7	9	0						9		
Other					1	0						1		
							1x 999							

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: IFT1/19 - Immunophenotypisation

Dead line: 15.04.2019

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability								
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(257) NK cells</b>					100							100	90	90%	
Samples and groups	[%]														
<b>Sample A</b>		21,1	1,5	7,2	100		CVP	21,1	0,37	26%	15,6	26,6	100	98	98%
(12) Beckman Coulter		21,1	1,4	6,7	50	0							50		
(36) Immunotech		21,3	1,8	8,3	5	0							5		
(88) Becton Dickinson		21,2	1,5	7,1	27	0							27		
(177) MINDRAY		21,5	3,7	17	7	0							7		
(190) Exbio Praha		20,9	1,2	5,8	10	0							10		
Other					1	0							1		
							1x 999								
<b>Sample B</b>		9,54	1,3	14	100		CVP	9,54	0,32	26%	7,05	12,1	100	91	91%
(12) Beckman Coulter		9,68	1,2	12	50	0							50		
(36) Immunotech		9,73	1,9	19	5	0							5		
(88) Becton Dickinson		9,71	1,1	11	27	0							27		
(177) MINDRAY		9,66	1,5	16	7	0							7		
(190) Exbio Praha		8,15	1,5	19	10	0							10		
Other					1	0							1		
							1x 999								

st\_kn\_p

End of report

Printed: 21.04.2019